Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from tocilizumab to sarilumab in stable rheumatoid arthritis
NL-OMON22277Recruiting
- Sponsor
- Sint Maartenskliniek
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of sarilumab and tocilizumab in rheumatoid arthritis (RA), sponsored by Sint Maartenskliniek. Primary endpoints: Change in DAS28-CRP from baseline to month 6 and Persistence with sarilumab at month 6. Started Dec 2019; status: recruiting.
02
Drugs
sarilumabtocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON22277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22277.